trimetazidine

Trimetazidine dihydrochloride (Vastarel F) can improve myocardial glucose utilization by inhibiting fatty acid metabolism. Trimetazidine is the first cytoprotective anti-ischemic agent, also used as a vasodilator in ischemic heart disease or angina.

Trimetazidine is a non-haemodynamic antianginal agent that selectively inhibits the mitochondrial enzyme 3-ketoacyl coenzyme A thiolase (LC 3-KAT), thereby preventing β-oxidation of free fatty acids, with an IC50 value of 75 nM. Trimetazidine prevents ischaemia-reperfusion injury by altering cardiac metabolism, exhibiting antioxidant and anti-ischaemic effects.

TriMetazidine EP Impurity-D is the starting material for the synthesis of TriMetazidine and an intermediate for the synthesis of various compounds.

Trimetazidine-N-oxide, the major active metabolite of Trimetazidine, is a selective long-chain inhibitor of 3-ketoyl coenzyme A thiolase (IC50: 75 nM) with anti-oxidant, anti-inflammatory, antinociceptive, and gastroprotective properties.

Trimetazidine-d8 Dihydrochloride is a deuterated compound of Trimetazidine Dihydrochloride. Trimetazidine Dihydrochloride has a CAS number of 13171-25-0. Trimetazidine dihydrochloride can improve myocardial glucose utilization by inhibiting fatty acid metabolism. Trimetazidine is the first cytoprotective anti-ischemic agent, also used as a vasodilator in ischemic heart disease or angina.